Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Editorial
Open Access

We’re not in Kansas anymore: ectopic dopaminergic terminals as an explanation for the positive symptoms in psychiatric pathology

Radu Gabriel Avramescu and Cecilia Flores
J Psychiatry Neurosci February 21, 2023 48 (1) E74-E77; DOI: https://doi.org/10.1503/jpn.230015
Radu Gabriel Avramescu
From the Douglas Mental Health University Institute, Montréal, Que., Canada (Avramescu, Flores); and the Department of Psychiatry and Department of Neurology and Neurosurgery, McGill University, Montréal, Que., Canada (Flores)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecilia Flores
From the Douglas Mental Health University Institute, Montréal, Que., Canada (Avramescu, Flores); and the Department of Psychiatry and Department of Neurology and Neurosurgery, McGill University, Montréal, Que., Canada (Flores)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Psychiatric disorders currently comprise more than 5% of the total disease burden worldwide,1 a share that is expected to increase as familiarity with guidelines for diagnosis becomes more widespread and the stigma associated with mental disorders continues to decrease. A number of mental disorders have been identified that have, maybe only temporarily, a high dopamine release component in brain regions associated with those disorders. Several of them, including schizophrenia, bipolar disorder, obsessive–compulsive disorder, Tourette syndrome and stuttering, respond well to antipsychotics or include antipsychotics as part of standard treatment.2,3 A common feature of these disorders is that blockade of postsynaptic dopamine receptors is proven to alleviate the most prominent positive symptoms. However, the more fundamental question is, where is all the extra dopamine coming from?

Possible mechanisms for the abnormally high dopamine release have been proposed previously, but none have been conclusively validated, nor are they generalizable across multiple disorders. In brief, these include increased firing of dopamine neurons, a functional defect in dopamine reuptake from the synaptic cleft, and alterations in postsynaptic dopamine receptor expression and signalling.4–6 These mechanistic interpretations were developed under the assumption that long-distance axonal pathfinding, most of which occurs during embryonic and fetal development, has ended by early childhood, generally before the onset of the first symptoms in any of the psychiatric disorders mentioned above. Recently, Reynolds and colleagues7,8 and Hoops and colleagues9 were able to demonstrate that, in mice, anterograde axon pathfinding of mesocortical dopamine neurons continues throughout adolescence, a finding not yet directly replicated in humans, but likely only because of the difficulty of doing equivalent experiments with human participants. In line with these findings, there has been some indirect evidence from nonhuman primates that showed the number of dopaminergic inputs in the prefrontal cortex (PFC) increases from adolescence to adulthood.10–12 We find the coinciding timing of adolescent anterograde dopaminergic pathfinding and the onset of symptoms in many of these hyperdopaminergic psychiatric disorders intriguing to say the least. In this editorial, we raise the possibility that alterations in dopamine axon targeting and growth in adolescence may be a key contributor to mental illnesses, particularly those with an onset in adolescence.

The ventral tegmental area (VTA) is the principal source of mesocorticolimbic dopaminergic terminals in the mammalian brain, with the mesolimbic pathway innervating primarily the ventral striatum and the mesocortical pathway innervating primarily the PFC. While neuronal input subgroups from other neuromodulatory systems13–15 achieve their final long-distance connectivity to the cortex by early postnatal life, the mesocorticolimbic dopamine system continues to mature well into adulthood. In rodents, dopamine axons destined to innervate the ventral striatum reach this region by early adolescence; however, mesocortical dopamine axons pass through this region and continue to grow toward the PFC throughout adolescence. Arrival of these latter dopaminergic terminals, and their subsequent synapsing in the PFC, coincide with behaviours that are refined in adolescence.16 In fact, the dopaminergic network in the brain has been previously described as a “plasticity network”17,18 that allows for local rewiring in response to environmental stimuli well into adult life. Recently, 2 studies19,20 have expanded on earlier histological descriptions of the rodent VTA and have resolved multiple different subpopulations of neurons,21 mostly dopaminergic. This finer division, contingent on transcriptomic identity, may prove useful in elucidating why some populations of dopaminergic neurons in the VTA complete their axonal pathfinding during embryonic and fetal life, while others undergo this process in the juvenile period or, exceptionally, as late as adolescence. These different neurodevelopmental timelines of dopaminergic axon pathfinding may help explain the various permissive periods of neuroplasticity in postnatal life.

In adolescent rodents, mesocortical dopamine terminals advance from the VTA through the nucleus accumbens and terminate in the PFC. It is conceivable that a number of these terminals can deviate from this intended target, either for genetic or environmental reasons, and synapse in unintended locations.7,8 At these aberrant sites, where dopaminergic axons are normally scarce or absent, there is now abnormal and elevated dopamine release. Khlghatyan and colleagues22 used a high-sensitivity approach to map D2 receptors in the human cortex and showed both widespread low-level cortical expression and multiple foci of D2 receptor clustering in areas not previously considered for significant dopamine signalling (insula, somatosensory, visual and auditory cortices). This shows that there are several brain areas that can detect/ encode subtle changes in dopamine signalling and that ectopic dopaminergic fibres that happen to intercede will likely be integrated into the local circuitry.

We posit that in the hyperdopaminergic disorders mentioned previously, and likely many others, a part of the pathology could be explained by dopaminergic terminals deviating from their intended target and ectopically innervating other brain areas. At these loci, the inclusion of aberrant dopamine signalling would alter the normal activity of the circuitry.23,24 In addition, the VTA has a finite number of dopaminergic cells, all of which have an intended and most likely unique neuro anatomical site, as few mesocorticolimbic dopaminergic neurons in rodents show collaterals.7,25–29 Ectopic dopamine terminals would no longer be available to synapse their intended target, as in the neurotypical brain, since they would now innervate an erroneous brain region. We suggest that the intended target of these terminals will have reduced dopamine innervation and present its own dysfunction,7,8 an additional insult stemming from the rerouting phenomenon, although some degree of compensation in local circuitry may occur. This interpretation is intriguing as it could help explain the dichotomy of symptoms often seen in some psychiatric disorders, namely positive and negative symptoms or, more simply, domains of hyperfunction and hypofunction. With that being said, many of the findings from studies in rodents need to be substantiated in humans, the constellation of symptoms is broad, and multiple other brain regions are implicated.

The following examples of psychopathological features are in line with our interpretation. A reported 60%–80%30 of patients diagnosed with a schizophrenia-spectrum disorder experience auditory hallucinations; however, they are also present in other mental disorders, such as bipolar depression (prevalence of 20%–50%), PTSD and major depression.31 These hallucinations are called paracusias and the underlying cause provoking them is not understood. Functional MRI (fMRI) studies have found both increased spontaneous activation of the primary auditory cortex in the absence of an auditory stimulus32 and decreased activity during stimulus presentation.33–35 The current interpretation for these seemingly paradoxical findings involves intrinsic stimulation (coming from a different brain area) and reduced extrinsic stimulation that follows the normal progression of the auditory pathway.33 While several neuroanatomical abnormalities have been found at the level of the Heschl gyrus (the primary auditory cortex36,37) and other associated areas (e.g., inferior part of the Broca area35,38), their underlying cause remains elusive. Moreover, there is indirect evidence that dopamine dysfunction is involved in these alterations.39 The major prevalence of auditory hallucinations in schizophrenia marks it as its most reliable feature40,41 and makes understanding them a stepping stone to elucidating the neurobiology of dopaminergic pathologies. One likely source of additional synaptic input into the Heschl gyrus may be ectopic dopaminergic axons, which could explain the dopaminergic bias of auditory hallucinations and the adolescent timeline of symptom onset.

Another common positive symptom often experienced by patients with schizophrenia-spectrum disorder is olfactory hallucination, with a lifetime prevalence of 35%42 and a past-month prevalence of up to 17%. The experience of smell is often not benign, but usually malodorous (e.g., rotten eggs, feces, diesel) and represents a type of phantosmia called cacosmia.43 The smell is a source of distress for the patient,44 as it seemingly follows the patient from room to room and cannot be escaped, leading to decreased food intake, low mood and further pathology. Olfactory hallucinations are associated with poorer outcomes in patients with schizophrenia,45,46 but standard anti-psychotic treatment works well to reduce and abolish the sen sation of cacosmia.47 While the source of this phenomenon can be placed along the olfactory tract, the proximity of the olfactory tubercle and the piriform cortex to the nucleus accumbens make them stand out. If we consider cacosmia through the lens of aberrant anterograde dopaminergic pathfinding, it is plausible that dopaminergic axons originating in the VTA and passing through the nucleus accumbens can deviate and synapse erroneously in an olfactory area.48,49 Alterations in the ol-factory dopaminergic system itself50 may also be at play, although maturational processes occurring in this system in adolescence, if any, remain to be elucidated. From the clinical perspective, in the average psychiatric patient, the onset of cacosmia occurs around age 19 years51 as a random occurrence unrelated to other stimuli, and it gradually worsens in the absence of treatment. We suggest that this sequence of events follows closely a situation in which dopamine axons could begin ectopically innervating these regions, possibly during adolescence, with more inputs occurring with advancing time.

Adolescence is a time of increased social and environmental exploration and interaction. During adolescence, males and females experience increased circulating sex hormones,52,53 which are well known for their altering effects on gene expression. Sex hormones have previously been suspected in the pathogenesis of psychiatric disorders owing to disease onset occurring shortly after puberty.54 For example, in individuals with schizophrenia,55 obsessive–compulsive disorder56 or bipolar disorder,57 the onset of symptoms begins in mid to late adolescence,58 a few months to a few years after the increase in sex hormones experienced at the beginning of puberty. Among their pleiotropic effects, sex hormones have long been shown to modulate dopamine transmission in the brain,59–61 with multiple mech anisms proposed to explain these findings. We suggest that sex hormones may trigger or stimulate the last period of anterograde dopamine axon growth, likely in conjunction with alterations in circulating human growth hormone and insulin.62,63

Conclusion

We propose the interesting possibility that altered dopaminergic states, as seen in some psychiatric disorders, may be explained, in part, by anterograde dopaminergic terminal migration and mistargeting occurring in mid to late adolescence. As this finding has been shown only in mice, it remains to be validated in humans; however, the coinciding timing of this phenomenon and the age of onset of altered dopaminergic psychiatric disorders is difficult to ignore. We posit that dopaminergic mistargeting may account, in part, for the presence of positive symptoms and that a reduction in terminals from intended targets may explain some of the negative symptoms and cognitive deficits observed in individuals with these disorders.

Footnotes

  • The views expressed in this editorial are those of the author(s) and do not necessarily reflect the position of the Canadian Medical Association or its subsidiaries, the journal’s editorial board or the Canadian College of Neuropsychopharmacology.

  • Competing interests: None declared.

  • Funding: The work and authors were supported by the National Institute on Drug Abuse (Grant number: R01DA037911), the Canadian Institutes of Health Research (Grant Number: MOP-74709) and the Natural Science and Engineering Research Council of Canada (Grant Number: 29822268).

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Roser M,
    2. Ritchie H,
    3. Spooner F
    . Our world in data. Burden of disease; 2021. Available: https://ourworldindata.org/burden-of-disease (accessed 2023 Jan. 20).
  2. ↵
    1. Remington G,
    2. Kapur S
    . Antipsychotics circa 2020: What are we thinking? Neuropharmacology 2020;175:108181.
    OpenUrl
  3. ↵
    1. Ratheesh A,
    2. Hett D,
    3. Ramain J,
    4. et al
    . A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders taskforce on early intervention. Int J Bipolar Disord 2023;11:1.
    OpenUrl
  4. ↵
    1. Howes OD,
    2. Shatalina E
    . Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance. Biol Psychiatry 2022;92:501–13.
    OpenUrl
    1. Abi-Dargham A,
    2. Rodenhiser J,
    3. Printz D,
    4. et al
    . Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104–9.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Seeman P,
    2. Kapur S
    . Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A 2000;97:7673–5.
    OpenUrlFREE Full Text
  6. ↵
    1. Reynolds LM,
    2. Pokinko M,
    3. Torres-Berrío A,
    4. et al
    . DCC receptors drive prefrontal cortex maturation by determining dopamine axon targeting in adolescence. Biol Psychiatry 2018;83:181–92.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Reynolds LM,
    2. Hernandez G,
    3. Popescu C,
    4. et al
    . Amphetamine disrupts dopamine axon growth in adolescence by a sex-specific mechanism. bioRxiv 2022 December 15 [Epub ahead of print]. doi:https://doi.org/10.1101/2022.12.14.520468
  8. ↵
    1. Hoops D,
    2. Reynolds LM,
    3. Restrepo-Lozano J-M,
    4. et al
    . Dopamine development in the mouse orbital prefrontal cortex is protracted and sensitive to amphetamine in adolescence. eNeuro 2018;5: ENEURO.0372-17.2017.
    OpenUrl
  9. ↵
    1. Lewis DA
    . Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology 1997;16:385–98.
    OpenUrlCrossRefPubMed
    1. Rosenberg DR,
    2. Lewis DA
    . Changes in the dopaminergic innervation of monkey prefrontal cortex during late postnatal development: a tyrosine hydroxylase immunohistochemical study. Biol Psychiatry 1994;36:272–7.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Rosenberg DR,
    2. Lewis DA
    . Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J Comp Neurol 1995;358: 383–400.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Levitt P,
    2. Moore RY
    . Development of the noradrenergic innervation of neocortex. Brain Res 1979;162:243–59.
    OpenUrlCrossRefPubMed
    1. Lidov HGW,
    2. Grzanna R,
    3. Molliver ME
    . The serotonin innervation of the cerebral cortex in the rat — an immunohistochemical analysis. Neuroscience 1980;5:207–27.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Naneix F,
    2. Marchand AR,
    3. Scala GD,
    4. et al
    . Parallel maturation of goal-directed behavior and dopaminergic systems during adolescence. J Neurosci 2012;32:16223–32.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Reynolds LM,
    2. Flores C
    . Mesocorticolimbic dopamine pathways across adolescence: diversity in development. Front Neural Circuits 2021;15:735625.
    OpenUrl
  14. ↵
    1. Larsen B,
    2. Luna B
    . Adolescence as a neurobiological critical period for the development of higher-order cognition. Neurosci Biobehav Rev 2018;94:179–95.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Barth B,
    2. Portella AK,
    3. Dubé L,
    4. et al
    . Early life origins of ageing and longevity. Heal Ageing Longev 2019;121–140.
  16. ↵
    1. Kim HJ,
    2. Kim M,
    3. Kang B,
    4. et al
    . Systematic analysis of expression signatures of neuronal subpopulations in the VTA. Mol Brain 2019;12:110.
    OpenUrl
  17. ↵
    1. Phillips RA,
    2. Tuscher JJ,
    3. Black SL,
    4. et al
    . An atlas of transcriptionally defined cell populations in the rat ventral tegmental area. Cell Rep 2022;39:110616.
    OpenUrlCrossRef
  18. ↵
    1. Garritsen O,
    2. van Battum EY,
    3. Grossouw LM,
    4. et al
    . Development, wiring and function of dopamine neuron subtypes. Nat Rev Neurosci 2023;1–19.
  19. ↵
    1. Khlghatyan J,
    2. Quintana C,
    3. Parent M,
    4. et al
    . High sensitivity mapping of cortical dopamine D2 receptor expressing neurons. Cereb Cortex 2019;29:3813–27.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gee S,
    2. Ellwood I,
    3. Patel T,
    4. et al
    . Synaptic activity unmasks dopamine D2 receptor modulation of a specific class of layer V pyramidal neurons in prefrontal cortex. J Neurosci 2012;32:4959–71.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Robinson SE,
    2. Sohal VS
    . Dopamine D2 receptors modulate pyramidal neurons in mouse medial prefrontal cortex through a stimulatory g-protein pathway. J Neurosci 2017;37:10063–73.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Beier KT,
    2. Steinberg EE,
    3. DeLoach KE,
    4. et al
    . Circuit architecture of VTA dopamine neurons revealed by systematic input-output mapping. Cell 2015;162:622–34.
    OpenUrlCrossRefPubMed
    1. Fallon JH
    . Collateralization of monoamine neurons: mesotelencephalic dopamine projections to caudate, septum, and frontal cortex. J Neurosci 1981;1:1361–8.
    OpenUrlAbstract/FREE Full Text
    1. Fallon JH,
    2. Loughlin SE
    . Monoamine innervation of the forebrain: collateralization. Brain Res Bull 1982;9:295–307.
    OpenUrlCrossRefPubMed
    1. Lammel S,
    2. Hetzel A,
    3. Häckel O,
    4. et al
    . Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 2008;57:760–73.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Swanson LW
    . The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 1982;9:321–53.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Lim A,
    2. Hoek HW,
    3. Deen ML,
    4. et al
    . Prevalence and classification of hallucinations in multiple sensory modalities in schizophrenia spectrum disorders. Schizophr Res 2016;176:493–9.
    OpenUrl
  25. ↵
    1. Choong C,
    2. Hunter MD,
    3. Woodruff PWR
    . Auditory hallucinations in those populations that do not suffer from schizophrenia. Curr Psychiatry Rep 2007;9:206–12.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Shergill SS,
    2. Brammer MJ,
    3. Williams SCR,
    4. et al
    . Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 2000;57:1033–8.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Kompus K,
    2. Westerhausen R,
    3. Hugdahl K
    . The “paradoxical” engagement of the primary auditory cortex in patients with auditory verbal hallucinations: a meta-analysis of functional neuroimaging studies. Neuropsychologia 2011;49:3361–9.
    OpenUrlCrossRefPubMed
    1. Dierks T,
    2. Linden DEJ,
    3. Jandl M,
    4. et al
    . Activation of Heschl’s gyrus during auditory hallucinations. Neuron 1999;22:615–21.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Shinn AK,
    2. Baker JT,
    3. Cohen BM,
    4. et al
    . Functional connectivity of left Heschl’s gyrus in vulnerability to auditory hallucinations in schizophrenia. Schizophr Res 2013;143:260–8.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Hirayasu Y,
    2. McCarley RW,
    3. Salisbury DF,
    4. et al
    . Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients. Arch Gen Psychiatry 2000;57:692–9.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Takahashi T,
    2. Sasabayashi D,
    3. Takayanagi Y,
    4. et al
    . Altered Heschl’s gyrus duplication pattern in first-episode schizophrenia. Schizophr Res 2021;237:174–81.
    OpenUrl
  31. ↵
    1. Sweet RA,
    2. Pierri JN,
    3. Auh S,
    4. et al
    . Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia. Neuropsychopharmacology 2003;28:599–609.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Cassidy CM,
    2. Balsam PD,
    3. Weinstein JJ,
    4. et al
    . A perceptual inference mechanism for hallucinations linked to striatal dopamine. Curr Biol 2018;28:503–514.e4.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Wing JK,
    2. Cooper JE,
    3. Sartorisu N
    . The measurement and classification of psychiatric symptoms. London: Cambridge University Press; 1974.
  34. ↵
    1. Lewandowski KE,
    2. DePaola J,
    3. Camsari GB,
    4. et al
    . Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singap 2009;38:383–5.
    OpenUrlPubMed
  35. ↵
    1. Kopala LC,
    2. Good KP,
    3. Honer WG
    . Olfactory hallucinations and ol-factory identification ability in patients with schizophrenia and other psychiatric disorders. Schizophr Res 1994;12:205–11.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Langdon R,
    2. McGuire J,
    3. Stevenson R,
    4. et al
    . Clinical correlates of olfactory hallucinations in schizophrenia. Br J Clin Psychol 2011;50: 145–63.
    OpenUrlPubMed
  37. ↵
    1. Meats P
    . Olfactory hallucinations. Br Med J (Clin Res Ed) 1988;296:645.
    OpenUrlFREE Full Text
  38. ↵
    1. Good KP,
    2. Whitehorn D,
    3. Rui Q,
    4. et al
    . Olfactory identification deficits in first-episode psychosis may predict patients at risk for persistent negative and disorganized or cognitive symptoms. Am J Psychiatry 2006;163:932–3.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Good KP,
    2. Sullivan RL
    . Olfactory function in psychotic disorders: insights from neuroimaging studies. World J Psychiatry 2015;5:210.
    OpenUrl
  40. ↵
    1. Kar S,
    2. Garg K,
    3. Tripathi A
    . Olfactory hallucinations in schizophrenia: does it carry any meaning? Int J Nutr Pharmacol Neurol Dis 2016;6:136.
    OpenUrl
  41. ↵
    1. Weismann M,
    2. Yousry I,
    3. Heuberger E,
    4. et al
    . Functional magnetic resonance imaging of human olfaction. [viii.]. Neuroimaging Clin N Am 2001;11:237–50.
    OpenUrlPubMed
  42. ↵
    1. Ismail II,
    2. Gad KA
    . Absent blood oxygen level–dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacosmia and cacogeusia after COVID-19 infection. JAMA Neurol 2021;78:609–10.
    OpenUrl
  43. ↵
    1. Turetsky BI,
    2. Hahn C-G,
    3. Borgmann-Winter K,
    4. et al
    . Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophr Bull 2009;35: 1117–31.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Lewandowski KE,
    2. DePaola J,
    3. Camsari GB,
    4. et al
    . Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singap 2009;38:383–5.
    OpenUrlPubMed
  45. ↵
    1. Kelsey TW,
    2. Li LQ,
    3. Mitchell RT,
    4. et al
    . A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years. PLoS One 2014;9:e109346.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Dimitrakakis C,
    2. Bondy C
    . Androgens and the breast. Breast Cancer Res 2009;11:212.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Brzezinski-Sinai NA,
    2. Brzezinski A
    . Schizophrenia and sex hormones: What is the link? Front Psychiatry 2020;11:693.
    OpenUrl
  48. ↵
    1. Chen L,
    2. Selvendra A,
    3. Stewart A,
    4. et al
    . Risk factors in early and late onset schizophrenia. Compr Psychiatry 2018;80:155–62.
    OpenUrl
  49. ↵
    1. Ruscio AM,
    2. Stein DJ,
    3. Chiu WT,
    4. et al
    . The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey replication. Mol Psychiatry 2010;15:53–63.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Manchia M,
    2. Maina G,
    3. Carpiniello B,
    4. et al
    . Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups. Int J Bipolar Disord 2017;5:28.
    OpenUrl
  51. ↵
    1. Solmi M,
    2. Radua J,
    3. Olivola M,
    4. et al
    . Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry 2022;27:281–95.
    OpenUrlPubMed
  52. ↵
    1. Di Paolo T
    . Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994;5:27–41.
    OpenUrlPubMed
    1. Sotomayor-Zarate R,
    2. Cruz G,
    3. Renard G,
    4. et al
    . Sex hormones and brain dopamine functions. Cent Nerv Syst Agents Med Chem 2014;14: 62–71.
    OpenUrlCrossRef
  53. ↵
    1. Barth C,
    2. Villringer A,
    3. Sacher J
    . Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci 2015;9:37.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Brambilla F,
    2. Guerrini A,
    3. Rovere C,
    4. et al
    . Growth hormone secretion in chronic schizophrenia. Neuropsychobiology 1975;1:267–76.
    OpenUrlPubMed
  55. ↵
    1. van Beveren NJM,
    2. Schwarz E,
    3. Noll R,
    4. et al
    . Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl Psychiatry 2014;4:e430.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 48 (1)
J Psychiatry Neurosci
Vol. 48, Issue 1
21 Feb 2023
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
We’re not in Kansas anymore: ectopic dopaminergic terminals as an explanation for the positive symptoms in psychiatric pathology
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
We’re not in Kansas anymore: ectopic dopaminergic terminals as an explanation for the positive symptoms in psychiatric pathology
Radu Gabriel Avramescu, Cecilia Flores
J Psychiatry Neurosci Feb 2023, 48 (1) E74-E77; DOI: 10.1503/jpn.230015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
We’re not in Kansas anymore: ectopic dopaminergic terminals as an explanation for the positive symptoms in psychiatric pathology
Radu Gabriel Avramescu, Cecilia Flores
J Psychiatry Neurosci Feb 2023, 48 (1) E74-E77; DOI: 10.1503/jpn.230015
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire